Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

26.57
-1.5300-5.44%
Post-market: 26.570.00000.00%19:18 EDT
Volume:1.84M
Turnover:49.36M
Market Cap:3.19B
PE:-9.20
High:27.83
Open:26.93
Low:26.23
Close:28.10
Loading ...

Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD

MT Newswires Live
·
17 Mar

Avidity Biosciences Announces Positive EXPLORE44 Trial Results

TIPRANKS
·
17 Mar

BRIEF-Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial

Reuters
·
17 Mar

Avidity Biosciences Inc - on Track for Year-End 2025 Bla Submission for Del-Zota in Dmd44

THOMSON REUTERS
·
17 Mar

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

GlobeNewswire
·
14 Mar

Citigroup Initiates Avidity Biosciences Inc at Buy With $70 Price Target

MT Newswires Live
·
13 Mar

ProQR Announces Year End 2024 Operating and Financial Results

GlobeNewswire
·
13 Mar

BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters
·
13 Mar

Avidity Biosciences initiated with an Outperform at BMO Capital

TIPRANKS
·
12 Mar

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Benzinga
·
11 Mar

Avidity Biosciences Is Maintained at Buy by B of A Securities

Dow Jones
·
11 Mar

Arrowhead announces topline results from ARO-C3 trial

TIPRANKS
·
10 Mar

Avidity Biosciences Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Avidity Biosciences initiated with an Outperform at Scotiabank

TIPRANKS
·
07 Mar

Avidity Biosciences (RNA) Gets a Buy from TD Cowen

TIPRANKS
·
06 Mar

Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

Business Wire
·
06 Mar

Circio’s Circular RNA Platform Shows Promising Advancements

TIPRANKS
·
05 Mar

Circio Holding ASA Gains Media Attention for Circular RNA Innovations

TIPRANKS
·
03 Mar

Avidity Biosciences (RNA) Gets a Buy from Wells Fargo

TIPRANKS
·
02 Mar

Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.
·
01 Mar